IOL

Latest News


CME Content


A foldable, hydrophobic acrylic IOL embedded with a small-aperture mask provided excellent visual acuity across all distances in patients who underwent monocular implantation after cataract surgery and was not associated with any visual symptoms that may occur with other presbyopia-correcting IOLs.

With a wide array of IOL options available to their foreign colleagues, U.S. ophthalmologists eagerly await the approval and availability of additional lenses.

Rayner Intraocular Lenses Ltd. have launched a new injector, RaySert Plus, in the United States market after receiving 510(k) clearance from the FDA.

The recent agreement between Valeant and Croma-which would provide for the distribution of Croma’s ophthalmology products in Western Europe-is expected to expand Bausch + Lomb’s (B + L) ophthalmic portfolio in the United States.

The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.

The Synchrony dual-optic accommodative intraocular lens (Abbott Medical Optics) seems to be clinically safe and effective after 2 years of follow-up. The visual function at intermediate and far improved rapidly postoperatively. Half of patients require a +1 D prescription for near vision.

When consulting with patients who present with decreased vision due to cataracts, ophthalmologists need to remember their role as physicians first, suggest the authors. The primary goal of the office visit is to address the complaint and the solution in entirety before moving into outcomes.

Among the 2013 ASCRS clinical survey results on astigmatism, findings showed that 57% of physicians saw benefits associated with femtosecond laser arcuate incisions compared with conventional manual incisions. Other trends were identified from the more than 1,000 physician responses.

An array of IOLs under development and in clinical trials show promise for correcting presbyopia or addressing other limitations of existing pseudophakic lenses.

Numerous reports show that phacoemulsification lowers IOP, but further research is needed to understand what mediates the change, according to Douglas J. Rhee, MD.

Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.

A light-adjustable IOL continues to show potential for delivering customized vision with predictable results.

A single-piece hydrophobic acrylic IOL has many features that make it a good choice for a monofocal implant in routine and challenging cataract surgery cases.

Secondary IOL implantation is widely accepted, especially in aphakic patients who have become contact lens intolerant or noncompliant. A number of studies on the topic, mostly from Western countries, have had small sample sizes, and the safety and efficacy of the procedure have not been well studied.

The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of cataract patients with pre-existing corneal astigmatism.

It is not always easy to fit the right IOL to the right patient to correct presbyopia. It is not that approved lenses do not work as expected, according to Richard Chu, DO, medical director, Chu Eye Associates, Fort Worth, TX, but that each lens has slightly different optical characteristics. Not every lens is right for every patient.

New clinical data suggest that an improved intraoperative aberrometer can help improve clinical outcomes for patients who receive an aspheric, hydrophobic IOL, said Dee Stephenson, MD, of Stephenson Eye Associates in Venice, FL.